209 related articles for article (PubMed ID: 27517489)
1. Suppression of c-Myc and RRM2 expression in pancreatic cancer cells by the sphingosine kinase-2 inhibitor ABC294640.
Lewis CS; Voelkel-Johnson C; Smith CD
Oncotarget; 2016 Sep; 7(37):60181-60192. PubMed ID: 27517489
[TBL] [Abstract][Full Text] [Related]
2. Glycogen synthase kinase-3β participates in acquired resistance to gemcitabine in pancreatic cancer.
Uehara M; Domoto T; Takenaka S; Bolidong D; Takeuchi O; Miyashita T; Minamoto T
Cancer Sci; 2020 Dec; 111(12):4405-4416. PubMed ID: 32986894
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of sphingosine kinase 2 downregulates the expression of c-Myc and Mcl-1 and induces apoptosis in multiple myeloma.
Venkata JK; An N; Stuart R; Costa LJ; Cai H; Coker W; Song JH; Gibbs K; Matson T; Garrett-Mayer E; Wan Z; Ogretmen B; Smith C; Kang Y
Blood; 2014 Sep; 124(12):1915-25. PubMed ID: 25122609
[TBL] [Abstract][Full Text] [Related]
4. The Sphingosine Kinase 2 Inhibitor ABC294640 Restores the Sensitivity of BRAFV600E Mutant Colon Cancer Cells to Vemurafenib by Reducing AKT-Mediated Expression of Nucleophosmin and Translationally-Controlled Tumour Protein.
Grbčić P; Eichmann TO; Kraljević Pavelić S; Sedić M
Int J Mol Sci; 2021 Oct; 22(19):. PubMed ID: 34639107
[TBL] [Abstract][Full Text] [Related]
5. Vasohibin 2 reduces chemosensitivity to gemcitabine in pancreatic cancer cells via Jun proto-oncogene dependent transactivation of ribonucleotide reductase regulatory subunit M2.
Tu M; Li H; Lv N; Xi C; Lu Z; Wei J; Chen J; Guo F; Jiang K; Song G; Gao W; Miao Y
Mol Cancer; 2017 Mar; 16(1):66. PubMed ID: 28327155
[TBL] [Abstract][Full Text] [Related]
6. Antitumor activity of sphingosine kinase 2 inhibitor ABC294640 and sorafenib in hepatocellular carcinoma xenografts.
Beljanski V; Lewis CS; Smith CD
Cancer Biol Ther; 2011 Mar; 11(5):524-34. PubMed ID: 21258214
[TBL] [Abstract][Full Text] [Related]
7. ABC294640, a sphingosine kinase 2 inhibitor, enhances the antitumor effects of TRAIL in non-small cell lung cancer.
Yang J; Yang C; Zhang S; Mei Z; Shi M; Sun S; Shi L; Wang Z; Wang Y; Li Z; Xie C
Cancer Biol Ther; 2015; 16(8):1194-204. PubMed ID: 26054751
[TBL] [Abstract][Full Text] [Related]
8. The Sphingosine Kinase 2 Inhibitor ABC294640 Reduces the Growth of Prostate Cancer Cells and Results in Accumulation of Dihydroceramides In Vitro and In Vivo.
Venant H; Rahmaniyan M; Jones EE; Lu P; Lilly MB; Garrett-Mayer E; Drake RR; Kraveka JM; Smith CD; Voelkel-Johnson C
Mol Cancer Ther; 2015 Dec; 14(12):2744-52. PubMed ID: 26494858
[TBL] [Abstract][Full Text] [Related]
9. Differential processing of let-7a precursors influences RRM2 expression and chemosensitivity in pancreatic cancer: role of LIN-28 and SET oncoprotein.
Bhutia YD; Hung SW; Krentz M; Patel D; Lovin D; Manoharan R; Thomson JM; Govindarajan R
PLoS One; 2013; 8(1):e53436. PubMed ID: 23335963
[TBL] [Abstract][Full Text] [Related]
10. Antitumor effect of the novel sphingosine kinase 2 inhibitor ABC294640 is enhanced by inhibition of autophagy and by sorafenib in human cholangiocarcinoma cells.
Ding X; Chaiteerakij R; Moser CD; Shaleh H; Boakye J; Chen G; Ndzengue A; Li Y; Zhou Y; Huang S; Sinicrope FA; Zou X; Thomas MB; Smith CD; Roberts LR
Oncotarget; 2016 Apr; 7(15):20080-92. PubMed ID: 26956050
[TBL] [Abstract][Full Text] [Related]
11. Targeting the sphingolipid metabolism to defeat pancreatic cancer cell resistance to the chemotherapeutic gemcitabine drug.
Guillermet-Guibert J; Davenne L; Pchejetski D; Saint-Laurent N; Brizuela L; Guilbeau-Frugier C; Delisle MB; Cuvillier O; Susini C; Bousquet C
Mol Cancer Ther; 2009 Apr; 8(4):809-20. PubMed ID: 19372554
[TBL] [Abstract][Full Text] [Related]
12. RNA interference targeting the M2 subunit of ribonucleotide reductase enhances pancreatic adenocarcinoma chemosensitivity to gemcitabine.
Duxbury MS; Ito H; Zinner MJ; Ashley SW; Whang EE
Oncogene; 2004 Feb; 23(8):1539-48. PubMed ID: 14661056
[TBL] [Abstract][Full Text] [Related]
13. Downregulation of Critical Oncogenes by the Selective SK2 Inhibitor ABC294640 Hinders Prostate Cancer Progression.
Schrecengost RS; Keller SN; Schiewer MJ; Knudsen KE; Smith CD
Mol Cancer Res; 2015 Dec; 13(12):1591-601. PubMed ID: 26271487
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of SRC tyrosine kinase impairs inherent and acquired gemcitabine resistance in human pancreatic adenocarcinoma cells.
Duxbury MS; Ito H; Zinner MJ; Ashley SW; Whang EE
Clin Cancer Res; 2004 Apr; 10(7):2307-18. PubMed ID: 15073106
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of ceramide glucosylation sensitizes lung cancer cells to ABC294640, a first-in-class small molecule SphK2 inhibitor.
Guan S; Liu YY; Yan T; Zhou J
Biochem Biophys Res Commun; 2016 Aug; 476(4):230-236. PubMed ID: 27221045
[TBL] [Abstract][Full Text] [Related]
16. Targeting the Warburg effect with a novel glucose transporter inhibitor to overcome gemcitabine resistance in pancreatic cancer cells.
Lai IL; Chou CC; Lai PT; Fang CS; Shirley LA; Yan R; Mo X; Bloomston M; Kulp SK; Bekaii-Saab T; Chen CS
Carcinogenesis; 2014 Oct; 35(10):2203-13. PubMed ID: 24879635
[TBL] [Abstract][Full Text] [Related]
17. Mucin 5AC Serves as the Nexus for β-Catenin/c-Myc Interplay to Promote Glutamine Dependency During Pancreatic Cancer Chemoresistance.
Ganguly K; Bhatia R; Rauth S; Kisling A; Atri P; Thompson C; Vengoji R; Ram Krishn S; Shinde D; Thomas V; Kaur S; Mallya K; Cox JL; Kumar S; Batra SK
Gastroenterology; 2022 Jan; 162(1):253-268.e13. PubMed ID: 34534538
[TBL] [Abstract][Full Text] [Related]
18. Pegylated arginine deiminase synergistically increases the cytotoxicity of gemcitabine in human pancreatic cancer.
Daylami R; Muilenburg DJ; Virudachalam S; Bold RJ
J Exp Clin Cancer Res; 2014 Dec; 33(1):102. PubMed ID: 25499121
[TBL] [Abstract][Full Text] [Related]
19. Targeting NFĸB mediated breast cancer chemoresistance through selective inhibition of sphingosine kinase-2.
Antoon JW; White MD; Slaughter EM; Driver JL; Khalili HS; Elliott S; Smith CD; Burow ME; Beckman BS
Cancer Biol Ther; 2011 Apr; 11(7):678-89. PubMed ID: 21307639
[TBL] [Abstract][Full Text] [Related]
20. Targeting ovarian cancer and chemoresistance through selective inhibition of sphingosine kinase-2 with ABC294640.
White MD; Chan L; Antoon JW; Beckman BS
Anticancer Res; 2013 Sep; 33(9):3573-9. PubMed ID: 24023282
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
